مواقع التدريسيينجامعة الكوفة
Khamaal Hussein Abod Al-Khafaji
Assistant Professor

Khamaal Hussein Abod Al-Khafaji

0Publications
0Lectures
0Interests
0News

About

Curriculum Vitae (C.V.):

the biography
Bachelor of Biology/ College of Science / University of Babylon / 2000. Master of Biology - Science - College of Science / Department of Biology / Reproductive Physiology / University of Kufa / 2014. Ph.D.in Biology - Medical Physiology / Department of Biology / College of Science / University of Kufa / 2018.

Research Interests

1

Publications

10
2019

Study role of hematological and leptin biomarkers in human infected with Entamoeba histolytica parasite

AuthorsSaleem Khteer Al-Hadraawy1, Khama'al Hussein Abod Al-Khafaji2, Fahim M. Deqeem3, and Naser Jawad Kadhim4
JournalIOP Conf. Series: Journal of Physics: Conf. Series 1294 (2019) 062032
Abstract

Abstract. The study was conducted on 58 out patients with Entamoeba histolytica parasite and 28 healthy people as control group to determine the influences of infected on levels of iron, ferritin and leptin in patients infected with E. histolytica in compared with healthy group. Who have visited Al-Sadder medical city and Al- Hakeem Hospital in Al- Najaf Province during the period from January till August 2016. This disease diagnosis by using the wet amount microscope for stool from patients. The results showed significant decrease (P<0.05) iron and ferritin in E. histolytica infection patients in compared to control group. Also the results showed significant decreased (P<0.05) in serum leptin of patients with E. histolytica in compared to control group

2018

Estimation of Endostatin level in pulmonary arterial hypertension patients and its relation with some parameters

AuthorsKhama'al Hussein Abod Al-Khafaji1, Mohammed Noori Al-Dujaili2, Arshad Noori Al-Dujaili3
JournalCurrent Issues in Pharmacy and Medical Sciences
Abstract

Biomarkers are attractive non-invasive tools for estimating and monitoring pulmonary arterial hypertension (PAH) disease and for predicting survival in patients with PAH; therefore, many studies encouraged the investigation of new biomarkers to facilitate the diagnosis of PAH. Endostatin (ES) is an endogenous inhibitor of angiogenesis. It is produced by proteolytic cleavage of the collagen XVIII that is present in both normal and cancerous tissue. In vitro examination shows that ES can manage endothelial cells (EC) physiology in ways that could influence angiogenesis. For example, solvent ES hinders EC movement and prompts improvements of the cytoskeleton that incorporate the loss of Actin stretch strands and central grips. Tis effect embraces restrictions on the α5β1integrins, Tropomyosin, and putative heparan sulfate proteoglycans. Consequences for the human EC cytoskeleton include Es-induced down-regulation of Mitogen-actuated Protein Kinase (MAPK), Focal Adhesion Kinase (FAK), the Urokinase Plasminogen Activator (uPA) System, and the RhoA GTPase. Human ES has likewise been shown in a few investigations to repress EC multiplication. Moreover, ES-instigated cell cycle capture in the G1 stage is joined by Cyclin D1 down-regulation. Of note, ES blocks the proliferation and organization of endothelial cells into new blood vessels, and in animal studies, ES also inhibits angiogenesis and the growth of both primary tumors and secondary metastasis. ES was initially identifed by its capacity to inhibit tumor angiogenesis in vitro and also in vivo. It can also be found in both healthy and patient’ serum, and has been detected in peripheral circulation. ES could be an attractive, non-invasive prognostic marker for some diseases, notably PAH. Terefore, the presented work is aimed at investigating the ES level in blood serum as a biomarker for detection, diagnosis and early treatment of PAH patients. In doing so, the association is ascertained between gender, age, body mass index (BMI), waist circumferences, smoking, types of PAH (primary and secondary) and this potential biomarker is assessed in PAH patients.

2018

Assessment of noggin level in pulmonary arterial hypertension patients

AuthorsKhama'al Hussein Abod Al-Khafaji1, Mohammed Noori Al-Dujaili2, Arshad Noori Ghani Al-Dujaili3
JournalCurrent Issues in Pharmacy and Medical Sciences
Abstract

Noggin (NOG) is a protein that is involved in the development of many body tissues, including nerve tissue, muscles, and bones. Te NOG protein plays a role in germ layer-specifc derivation of specialized cells. Via NOG, the formation of neural tissues, the notochord, hair follicles, and eye structures arise from the ectoderm germ layer, while noggin activity in the mesoderm gives way to the formation of cartilage, bone and muscle growth. In the endoderm, NOG is involved in the development of the lungs. NOG dimerizes by a core body, while two pairs of strands extend from it preceding by an N-terminal segment (called a clip segment) with approximately 20 amino acids. Tis clip twists around the BMP ligand and obstructs the growth factor surfaces from binding to both BMP receptors type I and type II. NOG binding to some BMPs inhibits these from combining and thus activating receptors of BMP, therefore, blocking non-Smad and Smad-dependent signaling. Te anti-proliferative noggin has particular effects in pulmonary arterial smooth muscle cells (PASMCs) that are exposed to specifcally down regulated hypoxia. Tis occurs together with the BMP4 up-regulation levels of protein, and this imbalance between NOG and BMP4 consequence results in the activation and development of PAH disease. Our study consists of numerous examinations so as to explore new biomarkers in order to determine onset of PAH, and to discover the relationship between NOG serum level and gender, age, body mass index (BMI), waist circumferences (WC), smoking, types of PAH primaries and secondaries, as well as their grade.

2018

Endoglin level in pulmonary arterial hypertension patients and its association with some criteria

AuthorsMohammed Noori Al-Dujaili, Khamaal Hussein Abod Al-Khafaji 2 Arshad Noori Ghani Al-Dujaili
JournalJ. Pharm. Sci. & Res
Abstract

Background and Objective: The study was done at the Cardiac Centre of Al-Sader Medical City Hospital in Al-Najaf Al-Ashraf City during the period from December 2016 to May 2017 to investigate the level of biomarker of endoglin for patients with pulmonary arterial hypertension as predictive indicators of the disease for detection, diagnosis and early treatment of patients. Materials and Methods:The study was applied on 88 people aged 30-69 years; 67 patients group with pulmonary arterial hypertension (PAH) and 21 healthy group. The group of patients was divided into subgroups based on gender, age, body mass index (BMI), waist circumference, smokers and non-smokers, type of primary and secondary arterial hypertension, types of secondary arterial hypertension, and disease grade. The healthy group was divided according to gender and age. Results :The study protruded a significant increase (p <0.05) in the level of Endoglin in the group of patients with pulmonary arterial hypertension compared to healthy, the female group compared to males, Smokers compared to non-smokers, and the group of two types of PAH disease found a significant increase in secondary compared to the primary PAH , the grade of disease group found increase in the severe level compared to moderate and mild and the age group at the age of 30 to 69 , but there is no significant increase between ages 30 to 49. While the level of Endoglin in the healthy group divided by gender and age have no significant differences that are almost constant. In comparing secondary PAH types, there was a significant increase (p<0.05) in the level of Endoglin for both Chronic obstructive pulmonary disease (COPD) and Left Heart Disease systolic dysfunction or diastolic dysfunction (compared with Valvular, Congenital and Pulmonary embolism. While there was no significant difference in the level of Endoglin between the Valvular, Congenital and Pulmonary embolism.The study explained that no significant difference in the level of Endoglin for the group of patients with pulmonary arterial hypertension divided by BMI group (normal weight, over weight, obese weight) and waist circumference group (70-80 cm , 81-90 cm, 91-100 cm, 101-110 cm, 111- 120 cm). Conclusion: The biomarker Endoglin consider warning sign as a prognostic marker for diagnosis PAH patients.

2018

Relationship Between Chordin Like-1 Protein Level and Patients with Pulmonary Arterial Hypertension Disease

AuthorsMohammed Noori Al-Dujaili , Khamaal Hussein Abod Al-Khafaji 2, Arshad Noori Ghani Al-Dujaili 3
JournalInternational Journal of Pharmaceutical Quality Assurance
Abstract

Pulmonary arterial hypertension (PAH) is a serene executioner, which can incite irreversible changes in pneumonic vascular structure and point of confinement, developing pulmonary vascular resistance (PVR), right ventricular disappointment, and death. Background and Objective: This study was done at the Cardiac Centre of Al-Sader Medical City Hospital in Al-Najaf Al-Ashraf province for the period from December 2016 to May 2017 to investigate the level of biomarker of Chordinlike-1for patients with pulmonary arterial hypertension as predictive indicators of the disease for detection, diagnosis and early treatment of patients. Materials and Methods: The study was applied on 88 people aged 30- 69 years; 67 patients group with pulmonary arterial hypertension (PAH) and 21 healthy group. The group of patients was divided into subgroups based on gender, age, body mass index (BMI), waist circumference, smokers and non-smokers, type of primary and secondary arterial hypertension, types of secondary arterial hypertension, and disease grade. The healthy group was divided according to gender and age. Results The study emerged a significant decrease (p <0.05) in the level of Chordin like-1 in the group of pulmonary arterial hypertension patients compared to the healthy group, the female group compared to the males, the age group at the age of 30 to 69, Secondary compared with a primary and the disease grade group was found that sever lower than moderate and mild.While the level of Chordin like-1 in the healthy group divided by gender and age have no significant differences.The study produced that in comparing secondary PAH types, there was a significant decrease (p <0.05) in the level of Chordin like-1 for both COPD and Left Heart Disease systolic dysfunction or diastolic dysfunction (LHD sys or dia) compared with Valvular, Congenital, and Pulmonary embolism. While there was no significant difference in the level of Chordin like-1between Valvular, congenital and pulmonary embolism. The study revealed no significant difference in the level of Chordin like-1 for the patients group of pulmonary arterial hypertension divided according to BMI group (normal weight, overweight, obese weight), waist circumference group (70-80 cm, 81-90 cm, 91-100 cm, 101-110 cm, 111-120 cm) and the group of smokers compared to non-smokers. conclusion: The biomarker Chordin like-1consider cautioning sign as a prognostic marker for determination PAH patients.

2016

EFFECT OF HOT AQUEOUS AND ETHANOL EXTRACTS OF CITRUS LIMON (L.) BURM SEEDS ON SOME HORMONAL LEVELS AND FERTILITY OF FEMALE ALBINO RATS

AuthorsKHAMA’AL HUSSEIN ABOOD AL-KHAFAJI, ARSHAD NOORI GHANI AL-DUJAILI AHMAD ABEIS MOTAR AL-SULTANEE
JournalAsian Jr. of Microbiol. Biotech.
Abstract

Abstract–This study was conducted in animals and plants laboratories and animal houses of the Department of Biology at the Faculty of Science / University of Kufa for the period from 25/09/2013 to 20/ 3/2014 to investigate the effect of hot aqueous and ethanol alcohol extracts of Citrus limon L. Burm seeds on some hormonal levels and fertility in female albino rats (Ratus ratus L.). In this study 60 rats were used aged 8 to 12 weeks and daily dosage orally by concentrations (250, 500) mg/kg of body weight of both extracts for two periods (10, 20) day was given. The current study revealed the occurrence of a significant decrease (p <0.05) in the level of each of follicle stimulating hormone (FSH) and luteinizing hormone (LH) and significant increase (p <0.05) in the level of estradiol hormone (E2) for both concentrations and dosing periods and two extracts compared with the control group. The concentration 500 mg/kg of body weight and dosing period 20 day of ethanol alcohol extract showed more significant effect (p <0.05) on all hormonal levels in current study compared with the concentration 250 mg/kg of body weight and dosing period 10 day of same extract and also with two concentrations 500 and 250 mg/kg of body weight and two dosing periods 10 and 20 day of hot aqueous extract of lemon seeds. The fertility test conducted on female rats treated by concentration 500 mg/kg of body weight for 20 days of both extracts did not show sperms in vaginal smears obtained from them only after a period of time in addition to that it suffered from the delay of pregnancy through daily monitoring for a period of 40 days thus, a decrease occurred in both the percentage of pregnancy and the numbers of fetuses in treated female compared with control group for both concentrations. The ethanol extract of the plant lemon seeds was the most efficient as antifertility in female rats compared hot aqueous extract.

2022

Effect of Smoking on Low-Density Lipoproteins Level in Human

AuthorsHussein Ali, E1, Hussein Abod Al-Khafaji, K2, Hassan Abood, A3
JournalArchives of Razi Institute
Date2022-09-01
Abstract

Abstract Smoking destroys the vascular system, increases plaque deposits in atherosclerosis, and increases inflammation. The present study was performed to determine the effect of smoking on the levels of low-density lipoprotein and very low-density lipoprotein in smokers. A cross-control study was carried out in the outpatient clinic in Baghdad, Iraq. The study was carried out 60 by individuals from February 2021 to July 2021. Participants in this study included adult smokers and non-smokers of both genders, and the levels of LDL and VLDL were determined using an Automatic Chemistry Analyze. The results revealed that the total number of smokers was 60 individuals from both genders; there was a significant difference in mean low-density lipoprotein and very low-density lipoprotein levels. There is a significant difference in LDL Values between non-smokers and smokers (129.853±7.880; P<0.05). Non-smokers showed lower LDL values (104.460±7.950; P<0.05). Regarding VLDL values, results revealed that smokers were showing higher values than a non-smoker (49.641±4.02), (28.986±1.676) respectively, P<0.05). LDL and VLDL levels are more prevalent in current cigarette smokers than in non-smokers. Heavy smokers have higher LDL and VLDL values for a cigarette than non-smokers, which is consistent with observations in other populations.

2022

Effect of Smoking on Low-Density Lipoproteins Level in Human

AuthorsHussein Ali, E1, Hussein Abod Al-Khafaji, K2, Hassan Abood, A3
JournalArchives of Razi Institute
Date2022-09-01
Abstract

Abstract Smoking destroys the vascular system, increases plaque deposits in atherosclerosis, and increases inflammation. The present study was performed to determine the effect of smoking on the levels of low-density lipoprotein and very low-density lipoprotein in smokers. A cross-control study was carried out in the outpatient clinic in Baghdad, Iraq. The study was carried out 60 by individuals from February 2021 to July 2021. Participants in this study included adult smokers and non-smokers of both genders, and the levels of LDL and VLDL were determined using an Automatic Chemistry Analyze. The results revealed that the total number of smokers was 60 individuals from both genders; there was a significant difference in mean low-density lipoprotein and very low-density lipoprotein levels. There is a significant difference in LDL Values between non-smokers and smokers (129.853±7.880; P<0.05). Non-smokers showed lower LDL values (104.460±7.950; P<0.05). Regarding VLDL values, results revealed that smokers were showing higher values than a non-smoker (49.641±4.02), (28.986±1.676) respectively, P<0.05). LDL and VLDL levels are more prevalent in current cigarette smokers than in non-smokers. Heavy smokers have higher LDL and VLDL values for a cigarette than non-smokers, which is consistent with observations in other populations.

2022

Effect of Smoking on Low-Density Lipoproteins Level in Human

AuthorsHussein Ali, E1, Hussein Abod Al-Khafaji, K2, Hassan Abood, A3
JournalArchives of Razi Institute
Date2022-09-01
Abstract

Abstract Smoking destroys the vascular system, increases plaque deposits in atherosclerosis, and increases inflammation. The present study was performed to determine the effect of smoking on the levels of low-density lipoprotein and very low-density lipoprotein in smokers. A cross-control study was carried out in the outpatient clinic in Baghdad, Iraq. The study was carried out 60 by individuals from February 2021 to July 2021. Participants in this study included adult smokers and non-smokers of both genders, and the levels of LDL and VLDL were determined using an Automatic Chemistry Analyze. The results revealed that the total number of smokers was 60 individuals from both genders; there was a significant difference in mean low-density lipoprotein and very low-density lipoprotein levels. There is a significant difference in LDL Values between non-smokers and smokers (129.853±7.880; P<0.05). Non-smokers showed lower LDL values (104.460±7.950; P<0.05). Regarding VLDL values, results revealed that smokers were showing higher values than a non-smoker (49.641±4.02), (28.986±1.676) respectively, P<0.05). LDL and VLDL levels are more prevalent in current cigarette smokers than in non-smokers. Heavy smokers have higher LDL and VLDL values for a cigarette than non-smokers, which is consistent with observations in other populations.

2022

Effect of Smoking on Low-Density Lipoproteins Level in Human

AuthorsHussein Ali, E1, Hussein Abod Al-Khafaji, K2, Hassan Abood, A3
JournalArchives of Razi Institute
Date2022-09-01
Abstract

Abstract Smoking destroys the vascular system, increases plaque deposits in atherosclerosis, and increases inflammation. The present study was performed to determine the effect of smoking on the levels of low-density lipoprotein and very low-density lipoprotein in smokers. A cross-control study was carried out in the outpatient clinic in Baghdad, Iraq. The study was carried out 60 by individuals from February 2021 to July 2021. Participants in this study included adult smokers and non-smokers of both genders, and the levels of LDL and VLDL were determined using an Automatic Chemistry Analyze. The results revealed that the total number of smokers was 60 individuals from both genders; there was a significant difference in mean low-density lipoprotein and very low-density lipoprotein levels. There is a significant difference in LDL Values between non-smokers and smokers (129.853±7.880; P<0.05). Non-smokers showed lower LDL values (104.460±7.950; P<0.05). Regarding VLDL values, results revealed that smokers were showing higher values than a non-smoker (49.641±4.02), (28.986±1.676) respectively, P<0.05). LDL and VLDL levels are more prevalent in current cigarette smokers than in non-smokers. Heavy smokers have higher LDL and VLDL values for a cigarette than non-smokers, which is consistent with observations in other populations.

Lectures

12

News & Announcements

2
News 2024-02-14

Doctor Assistant Professor

The scientific title of Assistant Professor was obtained

News 2021-01-18

[email protected]

The scientific title of Assistant Professor was obtained

View details